The Ebola outbreak in the DRC has claimed more than 3,400 lives and infected thousands more. Despite the scale of the outbreak, there is still no approved vaccine for the latest strain. Leanna Byrne examines what it takes and who pays to develop a vaccine. We look at what is slowing vaccine development and whether the limited commercial market for Ebola vaccines means governments, charities and international donors must step in to fund research.
(Photo: Sanitation measures underway at Bunia market to contain Ebola outbreak, Democratic Republic of the Congo, 23 May, 2026. Credit: EPA)
You can email the team: [email protected]
Producer: Matt Lines
(Correction, 16 September 2026: In this episode, first published on 15 September 2026, we incorrectly stated the size of Gavi's First Response Financing Fund. The correct figure is $500 million. We apologise for the error, which has been corrected.)
More episodes from "Business Daily"
Don't miss an episode of “Business Daily” and subscribe to it in the GetPodcast app.
